What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Telomerase in Cancer Cells: Mechanisms and Therapeutic Targeting

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Telomerase and Cancer

What is Telomerase?

Telomerase is a ribonucleoprotein enzyme complex that adds repetitive nucleotide sequences to the ends of linear chromosomes. The core enzyme consists of two essential components: the telomerase reverse transcriptase (TERT) protein, which provides the catalytic activity, and the telomerase RNA component (TERC), which serves as the template for synthesizing new telomeric DNA repeats. In humans, the telomeric repeat sequence is TTAGGG, and telomerase adds these hexanucleotide repeats processively to the 3' end of chromosome ends.

The catalytic cycle of telomerase is mechanistically distinct from other DNA polymerases. Rather than copying an existing DNA template, TERT uses the intrinsic RNA template within TERC to direct nucleotide addition. Each round of template copying adds one telomeric repeat, after which the enzyme translocates and repositions itself to add another repeat. This processivity allows a single telomerase enzyme to extend a telomere by hundreds of nucleotides in a single binding event.

Telomerase activity is tightly regulated during development. Most somatic cells in the adult human body have undetectable telomerase activity. However, certain cell types retain telomerase expression, including germ cells, activated lymphocytes, and adult stem cells in tissues with high turnover such as the bone marrow, intestinal epithelium, and skin. These cells require telomerase to maintain their proliferative capacity over the organism's lifetime.

Telomerase in Normal vs. Cancer Cells

The fundamental difference between normal and cancer cells regarding telomerase is one of regulation. In normal somatic cells, the TERT gene is transcriptionally silenced through a combination of promoter methylation, repressive histone modifications, and the absence of activating transcription factors. Even in telomerase-positive stem cells, activity is carefully calibrated to maintain telomere length without promoting uncontrolled proliferation.

Cancer cells subvert this regulation. Approximately 85–90% of all human cancers reactivate telomerase to high levels, enabling indefinite proliferation. This reactivation is so prevalent that telomerase is considered a near-universal hallmark of cancer. The remaining 10–15% of cancers maintain telomere length through a recombination-based mechanism called alternative lengthening of telomeres (ALT), which is discussed later.

The distinction matters clinically. Because normal somatic tissues have minimal telomerase activity, telomerase represents an attractive therapeutic target with a potentially wide therapeutic window. However, as we will see, the biology is more nuanced than simply "inhibit telomerase and kill cancer cells."

The Role of Telomeres in Cellular Aging

Telomere Structure and Function

Telomeres are specialized nucleoprotein structures at the ends of linear chromosomes. The DNA component consists of tandem arrays of the TTAGGG repeat, extending 5–15 kilobases in human somatic cells. The G-rich strand runs 5' to 3' toward the chromosome end, terminating in a single-stranded 3' overhang of 50–300 nucleotides.

This DNA is bound by a six-protein complex called shelterin, which includes TRF1, TRF2, POT1, TIN2, TPP1, and RAP1. Shelterin performs two critical functions. First, it protects chromosome ends from being recognized as double-strand DNA breaks, which would otherwise trigger the DNA damage response and cell cycle arrest. Second, it regulates telomerase access to the telomere, controlling the extent of telomere elongation.

The telomere can adopt a higher-order structure called a T-loop, where the single-stranded 3' overhang invades the double-stranded telomeric DNA, forming a displacement loop. This structure sequesters the chromosome end and further protects it from degradation and from activation of the DNA damage response.

The End-Replication Problem

The end-replication problem arises from the fundamental biochemistry of DNA polymerases. These enzymes synthesize DNA exclusively in the 5' to 3' direction and require a primer with a free 3' hydroxyl group to initiate synthesis. On the lagging strand, RNA primers are required for each Okazaki fragment. When the terminal RNA primer at the very end of the chromosome is removed, the resulting gap cannot be filled because there is no upstream primer to extend.

The result is that each round of DNA replication shortens the chromosome by approximately 50–200 base pairs. This loss occurs on the lagging strand, but the leading strand also experiences shortening due to post-replicative processing that resects the 5' ends to generate the proper 3' overhang structure.

Over successive cell divisions, telomeres progressively shorten. This shortening serves as a molecular clock, counting the number of divisions a cell has undergone. When telomeres become critically short, they lose the ability to bind shelterin effectively, and the exposed chromosome ends trigger a DNA damage response.

Cellular Senescence and Crisis

When telomeres reach a critically short length, typically below 4–5 kilobases, the cell enters a state called replicative senescence. This is a permanent cell cycle arrest mediated primarily by the p53 and retinoblastoma (Rb) tumor suppressor pathways. The short telomeres are recognized as DNA damage, activating ATM/ATR kinases, which phosphorylate and stabilize p53, leading to upregulation of p21 and cell cycle arrest.

Senescent cells remain metabolically active but no longer divide. This state acts as a tumor suppressor mechanism, preventing cells with damaged telomeres from proliferating. However, if the p53 or Rb pathways are inactivated by mutation, cells can bypass senescence and continue dividing. Telomeres continue to shorten, and the cells enter a state called crisis.

Crisis is characterized by massive genomic instability, including end-to-end chromosome fusions, dicentric chromosomes, and bridge-fusion-breakage cycles. Most cells in crisis die through apoptosis. However, rare cells can survive crisis by reactivating telomerase, which stabilizes their telomeres and confers unlimited proliferative potential. This event is a critical step in the progression from a normal cell to a cancer cell. The relationship between telomere dysfunction and genomic instability is a key component of the molecular basis of cancer.

Mechanisms of Telomerase Activation in Cancer

TERT Promoter Mutations

The most common genetic mechanism of telomerase reactivation in cancer is mutation of the TERT promoter. These mutations are found in approximately 20% of all cancers but are particularly frequent in certain tumor types, including melanoma (up to 70%), glioblastoma (up to 80%), bladder cancer (up to 65%), and thyroid cancer (up to 40%).

Two hotspot mutations dominate: C228T and C250T, named for their position relative to the transcription start site. Both mutations create de novo binding sites for E-twenty-six (ETS) transcription factors, particularly GABP (GA-binding protein). In the wild-type promoter, these ETS sites are absent. The mutations generate a consensus sequence that allows GABP to bind and drive strong transcriptional activation of TERT.

The functional consequence is a 2- to 10-fold increase in TERT mRNA expression compared to cells with wild-type promoters. This increased expression is sufficient to maintain telomere length and confer immortality. Importantly, these mutations are typically clonal, meaning they are present in all cancer cells within a tumor, suggesting they occur early in tumorigenesis and provide a strong selective advantage.

Epigenetic Regulation of TERT

Beyond mutations, epigenetic mechanisms regulate TERT expression in cancer. The TERT promoter resides in a CpG island, and its methylation status correlates with transcriptional activity. In normal somatic cells, the promoter is unmethylated but transcriptionally silent due to the absence of activating transcription factors and the presence of repressive histone marks.

In cancer cells, the TERT promoter often becomes methylated, particularly at CpG sites upstream of the transcription start site. This methylation paradoxically promotes transcription by preventing the binding of repressor proteins such as CTCF (CCCTC-binding factor). CTCF normally binds to the unmethylated promoter and maintains a repressive chromatin state. When methylation blocks CTCF binding, the promoter becomes accessible to activating transcription factors.

Histone modifications also play a role. Cancer cells often show increased histone acetylation at the TERT promoter, particularly at H3K9ac and H3K27ac, which are marks of active enhancers and promoters. Conversely, repressive marks such as H3K27me3, deposited by the Polycomb repressive complex 2 (PRC2), are reduced. These epigenetic changes work together with promoter mutations to achieve high-level TERT expression.

Alternative Lengthening of Telomeres (ALT)

Not all cancers rely on telomerase. Approximately 10–15% of cancers, particularly sarcomas, glioblastomas, and pancreatic neuroendocrine tumors, use the ALT mechanism. ALT is a homologous recombination-based pathway that maintains telomeres through copying telomeric DNA from one chromosome end to another.

Cells using ALT are characterized by several features: extremely long and heterogeneous telomeres, the presence of extrachromosomal telomeric repeats (ECTRs), and ALT-associated promyelocytic leukemia (PML) bodies, which are nuclear structures containing telomeric DNA, recombination proteins, and PML protein.

The molecular details of ALT are still being elucidated, but key players include the MRN complex (MRE11-RAD50-NBS1), BLM helicase, and RAD51 recombinase. These proteins mediate strand invasion and copying of telomeric sequences between sister chromatids or homologous chromosomes.

The existence of ALT has important therapeutic implications. Telomerase inhibitors would not be effective against ALT-positive tumors, and these cancers may even upregulate ALT in response to telomerase inhibition. Understanding which telomere maintenance mechanism a tumor uses is therefore critical for treatment planning.

Telomerase Function in Cancer Cell Immortality

Maintaining Telomere Length

The primary function of telomerase in cancer cells is to maintain telomere length, thereby preventing replicative senescence and crisis. By adding TTAGGG repeats to chromosome ends, telomerase counteracts the progressive shortening that occurs with each cell division.

The regulation of telomere length by telomerase is not a simple on-off switch. Rather, it is a finely tuned balance between telomere elongation and shortening. In cancer cells, telomerase activity is typically sufficient to maintain telomeres at a stable, albeit often shorter, length than in normal cells. This stable length allows indefinite proliferation without triggering the DNA damage response.

The process of telomere elongation by telomerase involves several steps. First, telomerase is recruited to the telomere through interactions between the TPP1 component of shelterin and the TEN domain of TERT. Once at the telomere, the 3' overhang is aligned with the RNA template in TERC, and nucleotide addition proceeds. After adding one repeat, telomerase can either dissociate or translocate to add another repeat.

The number of telomerase molecules at a telomere and their processivity determine the extent of elongation. Cancer cells often show increased telomerase processivity compared to normal cells, allowing more efficient telomere maintenance. This increased processivity may result from post-translational modifications of TERT, such as phosphorylation by Akt kinase.

Non-Canonical Functions of Telomerase

Telomerase has functions beyond telomere elongation that contribute to cancer biology. These non-canonical functions are particularly important because they may explain why some cancer cells with long telomeres still express high levels of telomerase.

TERT can localize to mitochondria, where it protects against oxidative stress-induced apoptosis. Mitochondrial TERT reduces reactive oxygen species production and inhibits the opening of the mitochondrial permeability transition pore, thereby increasing cell survival. This function is independent of its reverse transcriptase activity and may contribute to chemotherapy resistance.

TERT also modulates the DNA damage response. It can interact with and regulate the activity of DNA-dependent protein kinase (DNA-PK), a key enzyme in non-homologous end joining. Through this interaction, TERT may promote DNA repair and genomic stability, allowing cancer cells to survive genotoxic stress. This connection between telomerase and DNA repair is relevant to the broader relationship between DNA damage and cancer.

Additionally, TERT can act as a transcriptional co-regulator. It has been shown to interact with the Wnt/β-catenin signaling pathway, functioning as a co-factor for β-catenin-responsive genes. This interaction may promote cancer cell proliferation and stemness. TERT also modulates the expression of genes involved in cell cycle progression, including cyclin D1 and c-Myc.

These non-canonical functions complicate therapeutic strategies. Simply inhibiting telomerase catalytic activity may not fully abrogate the pro-survival and pro-proliferative effects of TERT. This is an important consideration in the molecular mechanism of cancer and its treatment.

Methods to Study Telomerase in Cancer

Telomeric Repeat Amplification Protocol (TRAP)

The TRAP assay is the gold standard for measuring telomerase activity in cell extracts and tissues. This technique exploits the ability of telomerase to add telomeric repeats to a synthetic oligonucleotide substrate, followed by PCR amplification of the extension products.

The assay begins with cell lysis in a buffer containing CHAPS detergent and protease inhibitors. A standardized amount of protein (typically 0.1–1 μg) is incubated with a biotinylated or unlabeled TS (telomerase substrate) oligonucleotide in the presence of dNTPs and a reaction buffer containing Tris-HCl (pH 8.3), MgCl₂, and KCl. The reaction proceeds at 30°C for 30 minutes, during which telomerase adds TTAGGG repeats to the TS primer.

Following the extension reaction, the products are amplified by PCR using the TS primer and a reverse primer (ACX) that anneals to the telomeric repeats. The PCR typically runs for 30–33 cycles with an annealing temperature of 59°C. The products are then separated by polyacrylamide gel electrophoresis and visualized by silver staining or fluorescence.

A critical feature of the TRAP assay is the inclusion of an internal control. A 36-base pair internal standard is co-amplified with the telomerase products to control for PCR inhibitors in the sample. The absence of this internal control band in a sample with no telomerase products indicates PCR inhibition rather than absent telomerase activity.

Quantification is achieved by densitometry of the characteristic six-base pair ladder pattern. Telomerase activity is expressed relative to a positive control cell line, such as HeLa cells, or as arbitrary units per microgram of protein.

Quantitative PCR for TERT Expression

While the TRAP assay measures enzymatic activity, quantitative PCR (qPCR) measures TERT mRNA expression. This approach is faster, more sensitive, and more amenable to high-throughput analysis than TRAP.

RNA is extracted from cells or tissues, reverse transcribed to cDNA, and TERT expression is quantified using TaqMan or SYBR Green chemistry. Primers are designed to span exon boundaries to avoid amplification of genomic DNA. A typical reaction uses 10–50 ng of cDNA, with cycling conditions of 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.

The choice of reference gene is critical. Commonly used references include GAPDH, ACTB, or B2M. However, these genes may vary between cancer types, so validation of reference gene stability is recommended. Results are expressed as relative expression using the 2^(-ΔΔCt) method, comparing cancer samples to normal controls.

It is important to note that TERT mRNA levels do not always correlate perfectly with telomerase activity. Post-transcriptional regulation, alternative splicing, and protein stability can all affect the relationship between mRNA and activity. Therefore, combining qPCR with TRAP provides a more complete picture.

Immunohistochemistry and In Situ Hybridization

Immunohistochemistry (IHC) detects TERT protein in tissue sections, providing spatial information about telomerase expression within a tumor. Formalin-fixed, paraffin-embedded tissue sections are incubated with a primary antibody against TERT, followed by a horseradish peroxidase-conjugated secondary antibody and chromogenic detection with diaminobenzidine (DAB).

TERT immunostaining is typically nuclear, reflecting its function at telomeres. However, cytoplasmic and mitochondrial staining can also be observed, consistent with the non-canonical functions discussed earlier. The interpretation of TERT IHC is complicated by the low abundance of TERT protein, even in telomerase-positive cells. Antibody specificity is a major concern, and validation with positive and negative controls is essential.

RNA in situ hybridization (ISH) using probes against TERT mRNA offers an alternative approach. The RNAscope technology uses a branched DNA amplification system that allows single-molecule detection of TERT transcripts in tissue sections. This method provides high sensitivity and specificity and can be quantified by counting punctate signals per cell.

Both IHC and ISH are valuable for clinical samples where fresh tissue for TRAP or qPCR is unavailable. They also allow correlation of telomerase expression with tumor histology and other biomarkers.

Telomerase as a Diagnostic and Prognostic Biomarker

Telomerase in Cancer Diagnosis

The near-universal expression of telomerase in cancer makes it an attractive diagnostic biomarker. Telomerase activity is detectable in malignant cells but not in most normal somatic cells, providing a potential means of distinguishing benign from malignant lesions.

In clinical practice, telomerase detection has been most extensively evaluated in urine cytology for bladder cancer diagnosis. Urine samples from patients with bladder cancer often contain exfoliated tumor cells with high telomerase activity. The TRAP assay on urine sediments has shown sensitivity of 70–90% for detecting bladder cancer, compared to 40–60% for conventional cytology. However, the assay's sensitivity to inhibitors in urine and the requirement for fresh samples have limited its widespread adoption.

Telomerase detection in fine-needle aspiration biopsies has been explored for thyroid nodules, where distinguishing benign from malignant lesions is challenging. Telomerase activity is elevated in malignant thyroid nodules but not in benign ones, potentially improving diagnostic accuracy. However, the clinical utility remains uncertain, and molecular testing for TERT promoter mutations has largely superseded activity assays in this setting.

Liquid biopsy approaches are emerging as a non-invasive diagnostic strategy. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) can be analyzed for TERT promoter mutations or TERT mRNA expression. Detection of TERT promoter mutations in cfDNA has shown promise for early cancer detection and monitoring, particularly in glioblastoma and bladder cancer. The sensitivity of these approaches depends on the tumor type and the amount of circulating tumor material.

Prognostic Value of Telomerase

Telomerase expression correlates with prognosis in several cancer types, although the relationship is not always straightforward. High TERT expression or telomerase activity is generally associated with worse outcomes, including reduced overall survival and increased risk of recurrence.

In glioblastoma, TERT promoter mutations are associated with distinct clinical outcomes depending on the molecular subtype. In IDH-wild-type glioblastoma, TERT promoter mutations are associated with poor prognosis, whereas in IDH-mutant tumors, they are associated with better outcomes. This paradoxical finding highlights the importance of considering telomerase status within the broader molecular context of the tumor.

In melanoma, TERT promoter mutations are associated with increased tumor thickness and ulceration, both markers of aggressive disease. Patients with TERT promoter-mutant melanomas have reduced disease-free and overall survival compared to those with wild-type tumors.

The prognostic value of telomerase may also depend on the balance between telomerase activity and telomere length. Tumors with high telomerase activity but short telomeres may behave differently from those with long telomeres. Short telomeres in the presence of high telomerase activity may indicate ongoing genomic instability, which could promote tumor evolution and aggressiveness.

Therapeutic Strategies Targeting Telomerase

Telomerase Inhibitors

Small molecule inhibitors of telomerase have been developed with the goal of blocking telomere elongation and inducing senescence or crisis in cancer cells. The most clinically advanced is imetelstat (GRN163L), a 13-mer oligonucleotide that binds to the RNA template of TERC with high affinity. Imetelstat acts as a competitive inhibitor, preventing telomerase from binding to the telomere and adding repeats.

Imetelstat has shown activity in clinical trials for myelofibrosis and essential thrombocythemia, where it reduces malignant cell burden and improves symptoms. However, its efficacy in solid tumors has been more limited. This may reflect the long lag time required for telomere shortening to reach critical levels in tumors with long telomeres.

Nucleoside analogs such as 6-thio-dG (6-thio-2'-deoxyguanosine) are incorporated into telomeric DNA during telomerase-mediated elongation. Once incorporated, these modified nucleotides cause telomere dysfunction and rapid cell death, rather than gradual telomere shortening. This mechanism may provide more rapid anti-tumor effects than competitive inhibitors.

BIBR1532 is a small molecule that binds to the TERT protein and inhibits its catalytic activity. While potent in vitro, its poor pharmacokinetic properties have limited its clinical development. Nevertheless, it remains a valuable tool for studying telomerase biology in the laboratory.

Immunotherapy Targeting Telomerase

Telomerase is an attractive target for cancer immunotherapy because it is a tumor-associated antigen expressed at high levels in cancer cells but minimally in normal tissues. Several immunotherapeutic approaches have been developed.

GV1001 is a 16-amino acid peptide derived from the active site of TERT. It binds to multiple HLA class II molecules and elicits CD4+ T cell responses. Clinical trials have evaluated GV1001 in pancreatic cancer and non-small cell lung cancer, with modest results. The vaccine is generally well tolerated, and some patients show immune responses associated with improved survival.

UV1 is a longer peptide vaccine covering multiple TERT epitopes, designed to elicit both CD4+ and CD8+ T cell responses. It is being evaluated in combination with immune checkpoint inhibitors in several cancer types. The rationale is that TERT-specific T cells can recognize and kill telomerase-expressing cancer cells, while checkpoint inhibitors prevent T cell exhaustion.

Adoptive cell therapy using T cells engineered to express TERT-specific T cell receptors (TCRs) is another approach. These TCR-transduced T cells can recognize TERT peptides presented on HLA molecules by cancer cells. However, the low density of TERT peptide-MHC complexes on cancer cells and the potential for on-target, off-tumor toxicity against telomerase-positive stem cells remain concerns.

Challenges and Future Directions

Telomerase inhibition faces several biological challenges. First, the lag time between telomerase inhibition and telomere shortening may be too long for clinical benefit in patients with advanced disease. Tumors with long telomeres may require many cell divisions before telomeres become critically short.

Second, cancer cells can develop resistance to telomerase inhibitors through activation of ALT. This alternative pathway can maintain telomere length in the absence of telomerase, rendering telomerase inhibitors ineffective. Combination strategies targeting both telomerase and ALT may be necessary.

Third, the non-canonical functions of TERT complicate the therapeutic picture. Even if telomerase catalytic activity is inhibited, TERT's effects on mitochondrial function, DNA repair, and gene expression may continue to promote cancer cell survival. This is particularly relevant given the role of telomerase in the biology of cancer beyond telomere maintenance.

Future directions include the development of agents that degrade TERT protein rather than simply inhibiting its catalytic activity. Proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to TERT could achieve this goal. Additionally, combining telomerase inhibitors with DNA-damaging agents or checkpoint inhibitors may enhance efficacy by simultaneously targeting multiple survival pathways.

Common Pitfalls and Misconceptions

Telomerase is Not Only in Cancer

A common misconception is that telomerase is exclusively expressed in cancer cells. In reality, telomerase is present in normal stem cells, germ cells, and activated lymphocytes. This has important therapeutic implications: telomerase inhibitors may cause side effects in tissues that depend on telomerase-positive stem cells, such as the bone marrow and intestinal epithelium.

In clinical trials of imetelstat, thrombocytopenia (low platelet count) and neutropenia (low neutrophil count) were observed, consistent with effects on hematopoietic stem cells. These side effects are manageable but illustrate that telomerase inhibition is not entirely cancer-specific.

Not All Cancers Use Telomerase

Approximately 10–15% of cancers maintain telomeres through the ALT mechanism and do not express telomerase. These tumors are typically of mesenchymal origin, including osteosarcomas, soft tissue sarcomas, and some glioblastomas.

The distinction between telomerase-positive and ALT-positive tumors is clinically relevant. Telomerase inhibitors would not be expected to benefit patients with ALT-positive tumors. Moreover, inhibiting telomerase in a mixed tumor could select for ALT-positive clones, leading to treatment resistance.

Telomerase Inhibition Does Not Kill Cells Immediately

Telomerase inhibitors do not cause rapid cancer cell death. Instead, they require multiple cell divisions for telomeres to shorten to critical lengths. A cancer cell with 10 kilobase telomeres losing 100 base pairs per division would require approximately 100 divisions to reach crisis. This process could take months in vivo.

This slow kinetics is a major limitation of telomerase inhibitors as monotherapy. It also explains why clinical trials have shown modest results in advanced cancers, where rapid tumor growth outpaces the effects of telomere shortening. Combining telomerase inhibitors with conventional chemotherapy or immunotherapy may be necessary to achieve meaningful clinical benefit.

Telomerase Activity and TERT Expression Are Not Always Correlated

Students often assume that measuring TERT mRNA is equivalent to measuring telomerase activity. However, telomerase activity is regulated at multiple levels beyond transcription. Alternative splicing of TERT mRNA can produce catalytically inactive isoforms, and post-translational modifications such as phosphorylation can modulate activity.

Additionally, the assembly of the telomerase holoenzyme requires the proper stoichiometry of TERT, TERC, and accessory proteins such as dyskerin. Overexpression of TERT alone does not always result in increased telomerase activity if other components are limiting.

The TRAP Assay Has Technical Pitfalls

The TRAP assay is technically demanding and prone to artifacts. PCR inhibitors in tissue extracts can produce false-negative results, which is why the internal control is essential. Conversely, carryover contamination from previous reactions can produce false-positive results. Strict laboratory practices, including separate areas for reaction setup and product analysis, are required.

Quantification of TRAP results is also challenging. The assay is semi-quantitative at best, and comparisons between samples require careful normalization to protein concentration and internal controls. For precise quantification, the TRAP assay can be modified to use real-time PCR detection, but this approach has its own complexities.

Summary and Key Takeaways

Telomerase is a ribonucleoprotein enzyme that maintains telomere length by adding TTAGGG repeats to chromosome ends. Its reactivation in approximately 85–90% of cancers is a critical step in cellular immortalization, allowing cancer cells to evade the replicative senescence that limits normal cell proliferation.

The mechanisms of telomerase reactivation include TERT promoter mutations that create ETS transcription factor binding sites, epigenetic changes that relieve transcriptional repression, and activation of signaling pathways that promote TERT expression. A minority of cancers use the ALT pathway instead of telomerase.

Telomerase contributes to cancer biology through both canonical telomere maintenance and non-canonical functions, including mitochondrial protection, DNA repair modulation, and transcriptional regulation. These functions complicate therapeutic strategies and may explain resistance to telomerase inhibition.

The study of telomerase in cancer relies on techniques including the TRAP assay for activity, qPCR for mRNA expression, and IHC/ISH for spatial localization. Telomerase has diagnostic and prognostic value, but its clinical utility depends on the cancer type and molecular context.

Therapeutic approaches targeting telomerase include small molecule inhibitors, nucleoside analogs, and immunotherapies. These strategies face challenges including slow kinetics, ALT-mediated resistance, and potential toxicity to telomerase-positive normal stem cells.

Frequently Asked Questions

What is the function of telomerase in cancer cells?

Telomerase in cancer cells maintains telomere length by adding TTAGGG repeats to chromosome ends, preventing the progressive telomere shortening that would otherwise trigger replicative senescence or crisis. This allows cancer cells to proliferate indefinitely. Telomerase also has non-canonical functions, including protection against oxidative stress, modulation of DNA repair, and regulation of gene expression, which contribute to cancer cell survival and growth.

Why is telomerase reactivated in cancer cells?

Telomerase is reactivated in cancer cells through several mechanisms. The most common are mutations in the TERT promoter that create binding sites for ETS transcription factors, particularly GABP. Epigenetic changes, including promoter methylation and histone modifications, also contribute by relieving transcriptional repression. These changes allow high-level TERT expression, which is necessary for telomere maintenance and unlimited proliferation.

How is telomerase activity measured in cancer research?

Telomerase activity is most commonly measured using the TRAP assay, which detects the addition of telomeric repeats to a synthetic substrate followed by PCR amplification. TERT mRNA expression can be quantified by qPCR, and TERT protein can be detected by immunohistochemistry. Each method has advantages and limitations, and combining approaches provides a more complete picture of telomerase status.

Is telomerase present in all cancer cells?

No. Approximately 85–90% of cancers express telomerase, but 10–15% maintain telomeres through the ALT mechanism, which uses homologous recombination rather than telomerase. ALT-positive tumors are more common among sarcomas and some glioblastomas. The presence of ALT has therapeutic implications, as telomerase inhibitors would not be effective against these tumors.

Can telomerase be used as a cancer biomarker?

Telomerase has potential as a diagnostic and prognostic biomarker. Telomerase activity or TERT expression can help distinguish malignant from benign lesions in some contexts, such as bladder cancer detection in urine. High telomerase expression is generally associated with worse prognosis, but the relationship depends on the cancer type and molecular context, as seen in glioblastoma where TERT promoter mutations have different prognostic implications depending on IDH status.

What are the side effects of telomerase inhibitors?

Telomerase inhibitors can affect normal tissues that depend on telomerase-positive stem cells. The most commonly observed side effects in clinical trials are thrombocytopenia (low platelet count) and neutropenia (low neutrophil count), reflecting effects on hematopoietic stem cells. Gastrointestinal side effects may also occur due to effects on intestinal stem cells. These side effects are generally manageable but limit the dose and duration of treatment.

Does telomerase have functions other than telomere elongation?

Yes. TERT has several non-canonical functions independent of its reverse transcriptase activity. It can localize to mitochondria and protect against oxidative stress-induced apoptosis. It interacts with DNA-PK to modulate DNA repair. It also acts as a transcriptional co-regulator, particularly in the Wnt/β-catenin pathway. These functions may contribute to cancer cell survival and may explain why telomerase inhibition alone is not always sufficient to kill cancer cells.

Key Takeaways

Telomerase is a ribonucleoprotein enzyme that maintains telomere length by adding TTAGGG repeats, and its reactivation is a hallmark of approximately 85–90% of cancers.
The end-replication problem causes progressive telomere shortening in normal cells, leading to replicative senescence or crisis, which acts as a tumor suppressor barrier.
TERT promoter mutations, particularly C228T and C250T, are the most common genetic mechanism of telomerase reactivation, creating ETS transcription factor binding sites.
Approximately 10–15% of cancers use the ALT pathway for telomere maintenance and do not express telomerase.
Telomerase has non-canonical functions in mitochondria, DNA repair, and transcriptional regulation that contribute to cancer biology beyond telomere maintenance.
The TRAP assay, qPCR, and immunohistochemistry are the main methods for studying telomerase in cancer research.
Telomerase inhibitors face challenges including slow kinetics, potential ALT-mediated resistance, and toxicity to telomerase-positive normal stem cells, making combination strategies an important area of investigation.